Parabilis Medicines, Inc. (NasdaqGS: PBLS)
Health Care · Biotechnology · US
$28.45
+0.07% today · -10.0% 1Y
Parabilis Medicines, Inc. (NasdaqGS: PBLS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.56B and employs 145 people.
Over the last twelve months the share price has lost 10.0%, trading between 22.66 and 42.49.
Tweenvest scores Parabilis Medicines, Inc. across four factors: quality 12/100, value 100/100. Its strongest factor is value.
PBLS price history
Key figures
- Market cap
- $3.56B
- Revenue (TTM)
- $2.26M
- P/E
- -20.90
- EPS
- -22.78
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $42.49
- 52-week low
- $22.66
- Avg volume (3M)
- —
- Shares outstanding
- 125.26M
- Employees
- 145
- Next earnings
- —
About Parabilis Medicines, Inc.
Parabilis Medicines, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
- ISIN
- US6989551014
- Founded
- 2015
- Listed since
- Jun 10, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Disc Medicine, Inc.NasdaqGM: IRON | $3.79B | $83.23 | -4.42% |
| SELLAS Life Sciences Group, Inc.NasdaqCM: SLS | $3.66B | $14.86 | -17.21% |
| Relay Therapeutics, Inc.NasdaqGM: RLAY | $3.65B | $16.51 | +0.24% |
| Arcutis Biotherapeutics, Inc.NasdaqGS: ARQT | $3.57B | $28.26 | +2.65% |
| Beijing Tiantan Biological Products Co., Ltd.SHSE: 600161 | $3.56B | CN¥12.01 | -1.72% |
| Iovance Biotherapeutics, Inc.NasdaqGM: IOVA | $3.46B | $7.31 | -2.27% |
| Viridian Therapeutics, Inc.NasdaqCM: VRDN | $3.42B | $30.12 | +0.20% |
| Suzhou Zelgen Biopharmaceuticals Co., Ltd.SHSE: 688266 | $3.37B | CN¥85.05 | -2.92% |